|  |  |  |  |
| --- | --- | --- | --- |
| **Supplemental Table 1.** Baseline characteristics of the included patients in the matched cohort | | | |
| Variables | No-anticoagulation  (n = 18) | RCA  (n = 18) | P value |
| Male, n (%) | 10 (55.6%) | 12 (66.7%) | 0.733 |
| Age, years, mean ± SD | 47.9 ± 11.3 | 54.2 ± 10.5 | 0.090 |
| APACHE II score, mean ± SD | 25.1 ± 8.1 | 26.9 ± 9.2 | 0.542 |
| SOFA score, mean ± SD | 13.7 ± 5.7 | 12.2 ± 5.0 | 0.405 |
| Mechanical ventilation, n (%) | 15 (83.3%) | 15 (83.3%) | 1.0 |
| Vasopressor dependency, n (%) | 7 (38.9%) | 7 (38.9%) | 1.0 |
| Co-morbidity |
| Neurologic disease, n (%) | 13 (72.2%) | 9 (50%) | 0.171 |
| Post operation, n (%) | 6 (33.3%) | 7 (38.9%) | 0.729 |
| Liver failure, n (%) | 1 (5.6%) | 0 (0%) | 0.310 |
| Burn, n (%) | 1 (5.6%) | 2 (11.1%) | 0.546 |
| AKI, n (%) | 15 (83.3%) | 14 (77.8%) | 0.674 |
| Urine volume, mean ± SD | 2832.5 ± 1581.1 | 3310.3 ± 1951.1 | 0.425 |
| Max serum sodium, mean ± SD mEq/L | 175.0 ± 9.0 | 174.5 ± 11.8 | 0.883 |
| Serum sodium, mEq/L, mean ± SD | 175.0 ± 8.2 | 174.6 ± 11.9 | 0.910 |
| Serum potassium, mEq/L, mean ± SD | 3.8 ± 1.1 | 3.8 ± 0.8 | 0.986 |
| Serum urea, mmol/L, mean ± SD | 23.3 ± 21.7 | 16.1 ± 8.9 | 0.208 |
| Serum creatinine, μmol/L, mean ± SD | 213.3 ± 112.2 | 191.2 ± 113.5 | 0.564 |
| Serum ALB, g/L, mean ± SD | 38.8 ± 8.2 | 35.5 ± 4.9 | 0.166 |
| Hemoglobin (g/L), mean ± SD | 117.6 ± 33.8 | 115.4 ± 27.1 | 0.833 |
| [Platelet](javascript:;) (109/L), mean ± SD | 114.5 ± 92.3 | 117.6 ± 61.0 | 0.908 |
| PT(s), mean ± SD | 17.0 ± 10.8 | 15.0 ± 4.9 | 0.489 |
| APTT(s), mean ± SD | 29.6 ± 13.8 | 37.6 ± 29.2 | 0.303 |
| Serum total bilirubin，mmol/L, mean ± SD | 34.7 ± 76.8 | 22.3 ± 10.7 | 0.504 |
| Vascular access, femoral, n (%) | 18(100%) | 16(88.9%) | 0.486 |
| *APACHE II* the acute physiology and chronic health evaluation II, *SOFA* sequential organ failure assessment, *PT* prothrombin time, *APTT* activated partial thromboplastin time | | | |